Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double Blind, Placebo Controlled, Randomized Study of TroVax vs. Placebo in the First Line Treatment of Patients with Metastatic Colorectal Cancer Receiving Standard of Care

Next Previous
X
Search
Trial Profile

A Multicenter, Double Blind, Placebo Controlled, Randomized Study of TroVax vs. Placebo in the First Line Treatment of Patients with Metastatic Colorectal Cancer Receiving Standard of Care

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA 5T4 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FLAMENCO

    • Most Recent Events

    • 07 Jul 2012 Planned number of patients changed from 1300 to 1312 and addtional trial location (United Kingdom) added as reported by European Clinical Trials Database record.
    • 20 Jun 2012 Actual initiation date (11 Jul 2008) and trial location (Spain) added as reported by European Clinical Trials Database record.
    • 20 Jun 2012 Actual end date (31 Oct 2009) added as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top